1. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E6(R2). Guideline for good clinical practices. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2016. https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 12 Dec 2023.
2. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E8(R1). Guideline on general considerations for clinical studies. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2021. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf. Accessed 12 Dec 2023.
3. Food and Drug Administration. Guidance for industry: investigator responsibilities—protecting the rights, safety, and welfare of study subjects. FDA; 2009. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM187772.pdf. Accessed 12 Dec 2023.
4. Medicine and Healthcare Products Regulatory Agency. GCP inspection metrics report. Medicine and Healthcare Products Regulatory Agency; 2023. https://assets.publishing.service.gov.uk/media/64357bfe89f19f00133cfb40/GCP_inspection_metrics_2019-2020.pdf. Accessed 12 Dec 2023.
5. Food and Drug Administration. Clinical Investigator Inspection List (CLIIL). FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/clinical-investigator-inspection-list-cliil. Accessed 12 Dec 2023.